15-hydroxyprostaglandin dehydrogenase [NAD(+)] (15-PGDH) (EC 1.1.1.141) (Eicosanoid/docosanoid dehydrogenase [NAD(+)]) (EC 1.1.1.-) (EC 1.1.1.232) (Prostaglandin dehydrogenase 1) (Short chain dehydrogenase/reductase family 36C member 1)
1_MHVNG 6_ KVALV 11_ TGAAQ 16_ GIGRA 21_ FAEAL 26_ LLKGA 31_ KVALV 36_ DWNLE 41_ AGVQC 46_ KAALD 51_ EQFEP 56_ QKTLF 61_ IQCDV 66_ ADQQQ 71_ LRDTF 76_ RKVVD 81_ HFGRL 86_ DILVN 91_ NAGVN 96_ NEKNW 101_ EKTLQ 106_ INLVS 111_ VISGT 116_ YLGLD 121_ YMSKQ 126_ NGGEG 131_ GIIIN 136_ MSSLA 141_ GLMPV 146_ AQQPV 151_ YCASK 156_ HGIVG 161_ FTRSA 166_ ALAAN 171_ LMNSG 176_ VRLNA 181_ ICPGF 186_ VNTAI 191_ LESIE 196_ KEENM 201_ GQYIE 206_ YKDHI 211_ KDMIK 216_ YYGIL 221_ DPPLI 226_ ANGLI 231_ TLIED 236_ DALNG 241_ AIMKI 246_ TTSKG 251_ IHFQD 256_ YDTTP 261_FQAKT
1: Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites (PubMed:10837478, PubMed:16757471, PubMed:16828555, PubMed:21916491, PubMed:25586183, PubMed:8086429). Decreases the levels of the pro-proliferative prostaglandins such as prostaglandin E2 (whose activity is increased in cancer because of an increase in the expression of cyclooxygenase 2) and generates oxo-fatty acid products that can profoundly influence cell function by abrogating pro-inflammatory cytokine expression (PubMed:15574495, PubMed:25586183). Converts resolvins E1, D1 and D2 to their oxo products, which represents a mode of resolvin inactivation. Resolvin E1 plays important roles during the resolution phase of acute inflammation, while resolvins D1 and D2 have a unique role in obesity-induced adipose inflammation (PubMed:16757471, PubMed:22844113)